StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)

Close on Nov 18, 2026Market cap $2.52MP/E –Yield –

NeuroSense Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$11.09M. The highest annual figure on record is -$1.24M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.09M–
FY2024Dec 31, 2024-$9.90M–
FY2023Dec 31, 2023-$12.05M–
FY2022Dec 31, 2022-$10.55M–
FY2021Dec 31, 2021-$2.99M–
FY2020Dec 31, 2020-$2.89M–
FY2019Dec 31, 2019-$1.24M–

More NeuroSense Therapeutics figures

See a number that looks wrong?